Show simple item record

dc.contributor.authorSoydal, Çiğdem
dc.contributor.authorÖzkan, Elgin
dc.contributor.authorNak, Demet
dc.contributor.authorElhan, Atilla Halil
dc.contributor.authorKÜçük, Nuriye Özlem
dc.contributor.authorKır, Kemal Metin
dc.date.accessioned2020-04-07T08:09:05Z
dc.date.available2020-04-07T08:09:05Z
dc.date.issued2019-05-29
dc.identifier.urihttps://doi.org/10.4274/mirt.galenos.2019.89410tr_TR
dc.identifier.urihttp://hdl.handle.net/20.500.12575/70897
dc.description.abstractObjectives: Endogenous hyperthyroidism accelerates bone turnover and shortens the normal bone remodeling cycle, which results in reduced bone density. It is estimated that suppressive levothyroxine (LT4) therapy also decreases bone density. The aim of this study was to define risk factors for osteoporosis development in patients under thyrotropin-stimulating hormone (TSH) suppressive treatment for differentiated thyroid cancer (DTC). Methods: Patients with a diagnosis of low or intermediate risk group DTC according to the American Thyroid Association 2015 guidelines and who have been receiving LT4 suppression therapy and were physically fit to undergo femur and lumbar vertebra bone density study were included in the study. Patients lacking information on demographic data, medical history, preoperative thyroid hormone status, or routine follow-up data were excluded from the study. A study form consisting of patient information on possible risk factors for osteoporosis such as gender, age, menopausal status, smoking, family history of osteoporosis, preoperative thyroid hormone status, postoperative hypoparathyroidism history, mean serum TSH levels, and duration of TSH suppression was created and filled out for each participant. Bone mineral densitometries of the femur and lumbar vertebrae were measured along with serum vitamin D and parathyroid hormone levels. Results: During TSH suppression (mean 7.2±4.5 years, range: 1-26), osteoporosis was detected in 89 (9.6%) patients. The mean time to develop osteoporosis was significantly different in patients with or without a family history of osteoporosis (15.3±0.4 versus 20.3±0.6 years; p=0.002). Similarly, the mean time to develop osteoporosis for was found to be significantly shorter in postmenopausal patients than that for premenopausal women (18.6±0.7 versus 20.4±0.4 years; p<0.001). Male gender (p<0.001), a family history of osteoporosis (p=0.001) and menopausal state (p<0.001) were identified as independent predictive factors for developing osteoporosis. Conclusion: Postmenopausal women, men, and patients with a family history who receive TSH-suppression treatment have a tendency to develop osteoporosis. Keywords: Differentiated thyroid carcinoma, osteoporosis, thyroid-stimulating hormone suppression treatmenttr_TR
dc.language.isoentr_TR
dc.publisherGalenostr_TR
dc.relation.isversionof10.4274/mirt.galenos.2019.89410tr_TR
dc.subjectOsteoporosistr_TR
dc.titleRisk factors for predicting osteoporosis in patients who receive thyrotropin suppressive levothyroxine treatment for differentiated thyroid carcinomatr_TR
dc.typeArticletr_TR
dc.contributor.departmentTıp Fakültesitr_TR
dc.contributor.authorID0000-003-0008-4972tr_TR
dc.identifier.volume28tr_TR
dc.identifier.startpage69tr_TR
dc.identifier.endpage75tr_TR
dc.relation.publicationcategoryGazete Makalesi - Ulusaltr_TR
dc.identifier.issn/e-issn2146-1414


Files in this item

This item appears in the following Collection(s)

Show simple item record